What We Do
At Botanix Pharma, we are dedicated to developing next generation therapeutics for the treatment of serious skin diseases.
Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles.
We are harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Graham has an executive career spanning 39 years in technology based companies, including various senior executive sales, marketing and product development positions with multi-nationals in the USA and Asia Pacific region respectively. In 2000 he became Managing Director of ASX listed company ipernica ltd, a diversified technology and intellectual property commercialisation group, where he had overall responsibility for the Company’s operations including strategy, corporate governance, human resources, investor relations, partnership development and acquisitions (including nearmap.com ASX:NEA).
His current non executive directorships include:
- Pointerra Ltd (ASX:3DP) (online solution for massive 3D point clouds)
- iperative Pty Ltd (specialist in monetizing intellectual property)
Graham has a Bachelor of Business (Accounting) degree and is a Fellow of the Australian Institute of Company Directors.
Mr Callahan is an experienced life sciences executive based in Philadelphia. He is the founding CEO of iCeutica Inc and Churchill Pharma Inc. and a co-inventor of some of the technologies that comprise the SoluMatrix Fine Particle Technology™ drug delivery platform that iCeutica uses to develop new pharmaceuticals. iCeutica has developed 3 products to date that have received FDA approval. He has more than 20 years legal, IP and investment management experience and is also a director of Glycan Bioscience LLC.
Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors and was General Manager and General Counsel with Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible or the lcensing programs that generated more that $120M in revenue.
Dr Bosch is a seasoned pharmaceutical executive with more than 20 years of experience in the industry, focusing on applications of nano technology to drug product development. Dr Bosch also works with iCeutica Inc. and is a co-inventor of the SoluMatrix™ technology and has been instrumental in the development and scale up of the platform and the development of the 3 FDA approved products that use that drug delivery technology.
Before iCeutica, he was Director of Pharmaceutical Research at Elan Corporation where he managed the development activities for four commercial products which incorporate nano technology. Dr Bosch was a co-founder of NanoSystems LLC in 1995 and a co-inventor of NanoCrystal® Technology.
Mr Towner has over 20 years’ experience in the corporate advisory and finance sectors. In March 2004, he founded and was executive director of bioMD Limited (now Admedus Limited) for over eight years. Mr Towner played an integral role in the merger of bioMD Limited with unlisted public company Allied Medical Limited.
He was appointed managing director of Triangle Energy (Global) Ltd in February 2015, and managed the Company’s transition from operating Indonesian based assets to establishing a portfolio of Australian oil and gas projects.
In 2009 Mr Towner founded Cornerstone Corporate Pty Ltd, consulting to Australian public companies on corporate planning & advisory, capital raisings and compliance. The Company was engaged to recapitalise and act as Lead Manager to ASX listed Bone Medical Limited completing a capital raising $3.8 million. Upon completion of the recapitalisation he accepted the role of non-executive chairman.
Mr Towner currently is a non-executive director of Triangle Energy and a non-executive director of the Telethon Type 1 Diabetes Family Centre.
Michael is an experienced senior executive with managerial and Board experience spanning 15 years. He has a background in drug regulation and biopharmaceutical industry, including senior roles in listed and private companies. Michael has worked extensively with life science start-ups across a range of technology platforms and has experience in drug discovery, preclinical and clinical development. He has guided and advised on the development of a range of NCEs (New Chemical Entities) through clinical trials, and possesses strong project management skills with a proven ability to raise capital. Prior to Botanix Pharmaceuticals (ASX:BOT), Michael held managerial and executive roles at Mimetica, Spinifex Pharmaceuticals and Cytopia and was a toxicology reviewer with the Drug Safety and Evaluation Branch of the Therapeutic Goods Administration. Michael has a doctor of philosophy from University of Technology Sydney and was a Postdoctoral Research fellow at the Australian Institute of Marine Science.
Botanix works with a range of partners for the supply of synthetic CBD, the manufacturing of GMP material in a DEA licensed facility for clinical trials and the conduct of well controlled human clinical trials.
Given that we work within a closely controlled industry which requires specific licensing and product handling, Botanix works with experienced DEA and FDA advisers and our partners to ensure compliance with relevant legal requirements.